Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 330


Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study.

Klein L, O'Connor CM, Leimberger JD, Gattis-Stough W, Piña IL, Felker GM, Adams KF Jr, Califf RM, Gheorghiade M; OPTIME-CHF Investigators.

Circulation. 2005 May 17;111(19):2454-60. Epub 2005 May 2.


Racial differences in the characteristics of patients admitted for acute decompensated heart failure and their relation to outcomes: results from the OPTIME-CHF trial.

Echols MR, Felker GM, Thomas KL, Pieper KS, Garg J, Cuffe MS, Gheorghiade M, Califf RM, O'Connor CM.

J Card Fail. 2006 Dec;12(9):684-8.


Admission or changes in renal function during hospitalization for worsening heart failure predict postdischarge survival: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF).

Klein L, Massie BM, Leimberger JD, O'Connor CM, Piña IL, Adams KF Jr, Califf RM, Gheorghiade M; OPTIME-CHF Investigators.

Circ Heart Fail. 2008 May;1(1):25-33. doi: 10.1161/CIRCHEARTFAILURE.107.746933.


Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study.

Felker GM, Benza RL, Chandler AB, Leimberger JD, Cuffe MS, Califf RM, Gheorghiade M, O'Connor CM; OPTIME-CHF Investigators.

J Am Coll Cardiol. 2003 Mar 19;41(6):997-1003.


Predictors of mortality after discharge in patients hospitalized with heart failure: an analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF).

O'Connor CM, Abraham WT, Albert NM, Clare R, Gattis Stough W, Gheorghiade M, Greenberg BH, Yancy CW, Young JB, Fonarow GC.

Am Heart J. 2008 Oct;156(4):662-73. doi: 10.1016/j.ahj.2008.04.030.


Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry.

Gheorghiade M, Abraham WT, Albert NM, Gattis Stough W, Greenberg BH, O'Connor CM, She L, Yancy CW, Young J, Fonarow GC; OPTIMIZE-HF Investigators and Coordinators.

Eur Heart J. 2007 Apr;28(8):980-8. Epub 2007 Feb 19.


Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE Trial.

Gheorghiade M, Rossi JS, Cotts W, Shin DD, Hellkamp AS, Piña IL, Fonarow GC, DeMarco T, Pauly DF, Rogers J, DiSalvo TG, Butler J, Hare JM, Francis GS, Stough WG, O'Connor CM.

Arch Intern Med. 2007 Oct 8;167(18):1998-2005.


Risk stratification after hospitalization for decompensated heart failure.

Felker GM, Leimberger JD, Califf RM, Cuffe MS, Massie BM, Adams KF Jr, Gheorghiade M, O'Connor CM.

J Card Fail. 2004 Dec;10(6):460-6.


The impact of arrhythmias in acute heart failure.

Benza RL, Tallaj JA, Felker GM, Zabel KM, Kao W, Bourge RC, Pearce D, Leimberger JD, Borzak S, O'connor CM, Gheorghiade M; OPTIME-CHF Investigators.

J Card Fail. 2004 Aug;10(4):279-84.


In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE).

Abraham WT, Adams KF, Fonarow GC, Costanzo MR, Berkowitz RL, LeJemtel TH, Cheng ML, Wynne J; ADHERE Scientific Advisory Committee and Investigators; ADHERE Study Group.

J Am Coll Cardiol. 2005 Jul 5;46(1):57-64.


Rationale and design of the OPTIME CHF trial: outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic heart failure.

Cuffe MS, Califf RM, Adams KF, Bourge RC, Colucci W, Massie B, O'Connor CM, Pina I, Quigg R, Silver M, Robinson LA, Leimberger JD, Gheorghiade M.

Am Heart J. 2000 Jan;139(1 Pt 1):15-22.


Impact of change in serum sodium concentration on mortality in patients hospitalized with heart failure and hyponatremia.

Madan VD, Novak E, Rich MW.

Circ Heart Fail. 2011 Sep;4(5):637-43. doi: 10.1161/CIRCHEARTFAILURE.111.961011. Epub 2011 Jun 14.


Outcomes associated with vasoactive therapy in patients with acute decompensated heart failure.

Arnold LM, Crouch MA, Carroll NV, Oinonen MJ.

Pharmacotherapy. 2006 Aug;26(8):1078-85.


Prognostic value of blood urea nitrogen in patients hospitalized with worsening heart failure: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) study.

Filippatos G, Rossi J, Lloyd-Jones DM, Stough WG, Ouyang J, Shin DD, O'connor C, Adams KF, Orlandi C, Gheorghiade M.

J Card Fail. 2007 Jun;13(5):360-4.


Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.

Anand IS, Bishu K, Rector TS, Ishani A, Kuskowski MA, Cohn JN.

Circulation. 2009 Oct 20;120(16):1577-84. doi: 10.1161/CIRCULATIONAHA.109.853648. Epub 2009 Oct 5.


Usefulness of anemia as a predictor of death and rehospitalization in patients with decompensated heart failure.

Felker GM, Gattis WA, Leimberger JD, Adams KF, Cuffe MS, Gheorghiade M, O'Connor CM.

Am J Cardiol. 2003 Sep 1;92(5):625-8.


Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure and chronic kidney disease.

Berger AK, Duval S, Manske C, Vazquez G, Barber C, Miller L, Luepker RV.

Am Heart J. 2007 Jun;153(6):1064-73.


Supplemental Content

Support Center